ES2146199T3 - Utilizacion de la arginina como inmunoestimulante. - Google Patents
Utilizacion de la arginina como inmunoestimulante.Info
- Publication number
- ES2146199T3 ES2146199T3 ES91902936T ES91902936T ES2146199T3 ES 2146199 T3 ES2146199 T3 ES 2146199T3 ES 91902936 T ES91902936 T ES 91902936T ES 91902936 T ES91902936 T ES 91902936T ES 2146199 T3 ES2146199 T3 ES 2146199T3
- Authority
- ES
- Spain
- Prior art keywords
- arginine
- ornithine
- immune response
- impaired
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000004475 Arginine Substances 0.000 title abstract 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title abstract 7
- 229960001438 immunostimulant agent Drugs 0.000 title 1
- 239000003022 immunostimulating agent Substances 0.000 title 1
- 230000003308 immunostimulating effect Effects 0.000 title 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 6
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 6
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract 6
- 229960003104 ornithine Drugs 0.000 abstract 6
- 230000028993 immune response Effects 0.000 abstract 4
- 230000001771 impaired effect Effects 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 241000282412 Homo Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pediatric Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
EL USO DE ARGININA COMO INMUNOESTIMULADOR LA PRESENTE INVENCION SE REFIERE AL TRATAMIENTO DE UNA RESPUESTA INMUNE HUMANA DETERIORADA O A LA REDUCCION DE LA GRAVEDAD DE LA RESPUESTA INMUNE HUMANA MEDIANTE LA ADMINISTRACION DE ARGININA O DE ORNITINA, O DE UN ANALOGO FUNCIONAL DE LA ARGININA O DE LA ORNITINA, O MEZCLAS DE LAS MISMAS, A SERES HUMANOS QUE PADECEN UNA RESPUESTA INMUNE DETERIORADA O QUE CORREN EL RIESGO DE SUFRIR UNA RESPUESTA INMUNE DETERIORADA. TAL TRATAMIENTO SE SUMINISTRA MEDIANTE LA ADMINISTRACION ENTERAL DE COMPOSICIONES SUPLIDAS CON ARGININA O CON ORNITINA, O CON ANALOGOS FUNCIONALES DE LA ARGININA O DE LA ORNITINA, O MEDIANTE LA ADMINISTRACION PARENTERAL DE SOLUCIONES DE AMINOACIDOS SUPLIDAS CON ARGININA O CON ORNITINA, O CON ANALOGOS FUNCIONALES DE LA ARGININA O DE LA ORNITINA, A PACIENTES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45899689A | 1989-12-29 | 1989-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2146199T3 true ES2146199T3 (es) | 2000-08-01 |
Family
ID=23822959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES91902936T Expired - Lifetime ES2146199T3 (es) | 1989-12-29 | 1990-12-28 | Utilizacion de la arginina como inmunoestimulante. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0507872B1 (es) |
| JP (1) | JP3287842B2 (es) |
| AT (1) | ATE192037T1 (es) |
| AU (1) | AU7148791A (es) |
| CA (1) | CA2071971C (es) |
| DE (1) | DE69033521T2 (es) |
| ES (1) | ES2146199T3 (es) |
| WO (1) | WO1991009524A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5292773A (en) * | 1990-02-14 | 1994-03-08 | Hirsch Gerald P | Treating aids and HIV infection with methionine |
| US5221668A (en) * | 1992-02-26 | 1993-06-22 | Abbott Laboratories | Nutritional product for trauma and surgery patients |
| US5276018A (en) * | 1992-07-17 | 1994-01-04 | Brigham And Women's Hospital | Composition comprising amino acids and methods for decreasing muscle breakdown |
| GB9512100D0 (en) * | 1995-06-14 | 1995-08-09 | Sandoz Nutrition Ltd | Improvements in or relating to organic compounds |
| GB9510037D0 (en) * | 1995-05-18 | 1995-07-12 | Sandoz Nutrition Ltd | Improvements in or relating to organic compounds |
| IT1277897B1 (it) * | 1995-08-03 | 1997-11-12 | Mendes Srl | Uso della l-carnitina,di suoi derivati e di loro sali farmaceuticamen- te accettabili in combinazione con farmaci antiretrovirali per ridurre |
| DE19528461A1 (de) * | 1995-08-03 | 1997-02-06 | Braun Melsungen Ag | Präparat zur Ernährung |
| GB2312621B (en) * | 1996-05-02 | 1998-03-11 | Pharma Nord Uk Limited | Anti-oxidant medicament |
| ATE298205T1 (de) * | 1999-01-29 | 2005-07-15 | Sportmedizin Team Vertriebs Gm | Zusammensetzung zur leistungsförderung bei sportlicher tätigkeit, ihre herstellung und verwendung als diätetisches lebensmittel |
| HK1044100B (en) * | 1999-04-27 | 2005-07-22 | Somalife Consulting Ltd. | Supplement for restoring growth hormone levels |
| DE10128934A1 (de) * | 2001-06-18 | 2003-02-06 | Bernhard Sibbe | Wirkstoffzusammensetzung zur Vorbeugung gegen Angina-Pectoris-Beschwerden |
| JP4603891B2 (ja) * | 2002-10-31 | 2010-12-22 | パク，レ−オク | 抗癌剤組成物 |
| JP4528925B2 (ja) * | 2003-05-30 | 2010-08-25 | 独立行政法人理化学研究所 | アミノ酸組成物及び補液 |
| BRPI0907107B8 (pt) * | 2008-02-08 | 2019-08-20 | Colgate Palmolive Co | composição, e, uso de uma composição para cuidado oral |
| WO2011021926A1 (en) * | 2009-08-21 | 2011-02-24 | N.V. Nutricia | Regulating the amino acid pool used for the acute-phase protein synthesis |
| EA201690987A1 (ru) | 2013-11-13 | 2016-10-31 | Новартис Аг | Низкодозовые иммуностимулирующие ингибиторы mtor и их применения |
| JP2016132622A (ja) * | 2015-01-16 | 2016-07-25 | イーエヌ大塚製薬株式会社 | 敗血症治療又は予防用栄養組成物 |
| WO2017123675A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| AU2018301668A1 (en) * | 2017-07-12 | 2019-12-19 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| WO2019035953A1 (en) * | 2017-08-18 | 2019-02-21 | Calwood Nutritionals, Llc | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH, TREATING SKIN, REDUCING WEAR AND DEGRADING FROM AGING AND EXPOSURE AND ENHANCING RECOVERY OF A STRESS SUCH AS EXERCISE AND TRAUMA |
| EP3703516A4 (en) * | 2017-11-02 | 2021-08-18 | BioVentures, LLC | USE OF AMINO ACID SUPPLEMENTATION FOR IMPROVED MUSCLE PROTEIN SYNTHESIS |
| EP4132299B1 (en) * | 2020-04-06 | 2025-06-11 | Société des Produits Nestlé S.A. | Vitality dietary supplement |
| DE102022004219B4 (de) | 2022-11-15 | 2024-07-18 | Peter Meyer | Aminosäurenkombination mit Vitamin C und B6 zur präventiven, kurativen und rehabilitativen Behandlung von Stoffwechselstörungen im Kohlenhydratstoffwechsel, Proteinstoffwechsel und Fettstoffwechsel sowie bei physischen und/oder psychischen Leistungsverlust. |
| CN118340757A (zh) * | 2023-12-25 | 2024-07-16 | 浙江大学 | 预防急性胰腺炎的药物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1177384B (it) * | 1984-12-12 | 1987-08-26 | Boeehringer Biochemia Robin Sp | Prodotti dietetici granulari a base di amminoacidi e procedimento per la loro preparazione |
| DE3603242A1 (de) * | 1986-02-03 | 1987-08-06 | Deutsches Krebsforsch | Verwendung von putrescin, ornithin und uridin allein oder in mischung, ggfs. zusammen mit lactat und/oder pyruvat zur steigerung der aktivitaet von helfer t-lymphozyten und davon abhaengiger anderer immunreaktionen |
-
1990
- 1990-12-28 AT AT91902936T patent/ATE192037T1/de not_active IP Right Cessation
- 1990-12-28 AU AU71487/91A patent/AU7148791A/en not_active Abandoned
- 1990-12-28 WO PCT/US1990/007689 patent/WO1991009524A1/en not_active Ceased
- 1990-12-28 EP EP91902936A patent/EP0507872B1/en not_active Expired - Lifetime
- 1990-12-28 JP JP50332791A patent/JP3287842B2/ja not_active Expired - Fee Related
- 1990-12-28 DE DE69033521T patent/DE69033521T2/de not_active Expired - Fee Related
- 1990-12-28 CA CA002071971A patent/CA2071971C/en not_active Expired - Fee Related
- 1990-12-28 ES ES91902936T patent/ES2146199T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0507872A1 (en) | 1992-10-14 |
| EP0507872A4 (en) | 1993-08-04 |
| JP3287842B2 (ja) | 2002-06-04 |
| EP0507872B1 (en) | 2000-04-26 |
| DE69033521D1 (de) | 2000-05-31 |
| CA2071971A1 (en) | 1991-06-30 |
| WO1991009524A1 (en) | 1991-07-11 |
| JPH05502881A (ja) | 1993-05-20 |
| AU7148791A (en) | 1991-07-24 |
| ATE192037T1 (de) | 2000-05-15 |
| CA2071971C (en) | 2001-11-20 |
| DE69033521T2 (de) | 2000-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU7148791A (en) | The use of arginine as an immunostimulator | |
| BR9913932A (pt) | Uso de análogos de glp-1 no tratamento de derrame | |
| KR930702022A (ko) | 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법 | |
| RU94038043A (ru) | Применение замещенных производных аденина для лечения множественного склероза | |
| KR960000924A (ko) | 인슐린 유사체 배합물 | |
| FI20001231A7 (fi) | 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina | |
| IT8321083A1 (it) | ANALOGHI RETRO-INVERTITI DEL PENTAPEPTIDE POTENZIANTE LA BRADICHININA BPP5a E METODI PER LA LORO PREPARAZIONE | |
| ES2181676T3 (es) | Diagnosis y tratamiento de enfermedades autoinmunitarias. | |
| RU94002475A (ru) | Фармацевтическая композиция и ее применение для лечения вирусных инфекций | |
| NO821832L (no) | Fremgangsmaate for fremstilling av allergenholdige kapsler | |
| RU95106651A (ru) | Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента | |
| DE69027031D1 (de) | Nicht glycosierte proteine, analoge des menschlichen interleukin-3 | |
| BR9707154A (pt) | Modulaç o da express o de citocina em th1/th2 por ribavirina e análogos de ribavirina em linfócitos t ativados | |
| ATE87484T1 (de) | Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| ES2146231T3 (es) | Polipeptidos derivados de la endonexina 2 y que presentan una actividad de receptor del virus de la hepatitis b, y su utilizacion en composiciones diagnosticas y farmaceuticas. | |
| DE69133077D1 (de) | Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung | |
| AR247404A1 (es) | Composicion peptidica de uso exclusivo para el diagnostico de la enfermedad de la malaria y procedimiento de sintesis de dicha composicion peptidica | |
| ES8608884A1 (es) | Un procedimiento de eliminacion del virus lav. | |
| DK148890D0 (da) | Farmaceutisk praeparat | |
| DE181050T1 (de) | 1-beta-d-ribofuranosyl-1,2,4-triazol-3-carboxamid fuer die verwendung in medizinischer behandlung von menschen. | |
| McDonald et al. | Focal upper limb neuropathy in a child | |
| Yaegaki et al. | The effect of mouthwash on oral malodour production | |
| FR2838965B1 (fr) | Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme | |
| DK0820308T3 (da) | Konjugat til behandling af inflammatoriske sygdomme | |
| JPS6438030A (en) | Preventing and treating agent for aids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 507872 Country of ref document: ES |